List of Excipients in API mavacamten
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing mavacamten
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Myokardia Inc | CAMZYOS | mavacamten | 73625-111 | CROSCARMELLOSE SODIUM | 2029-04-28 |
| Myokardia Inc | CAMZYOS | mavacamten | 73625-111 | FERRIC OXIDE RED | 2029-04-28 |
| Myokardia Inc | CAMZYOS | mavacamten | 73625-111 | FERRIC OXIDE YELLOW | 2029-04-28 |
| Myokardia Inc | CAMZYOS | mavacamten | 73625-111 | FERROSOFERRIC OXIDE | 2029-04-28 |
| Myokardia Inc | CAMZYOS | mavacamten | 73625-111 | GELATIN | 2029-04-28 |
| Myokardia Inc | CAMZYOS | mavacamten | 73625-111 | HYPROMELLOSE | 2029-04-28 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for mavacamten
Excipient focus: CROSCARMELLOSE SODIUM
mavacamten drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Myokardia Inc | mavacamten | 73625-111 |
| >Company | >Ingredient | >NDC |
mavacamten drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
mavacamten drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Myokardia Inc | mavacamten | 73625-111 |
| >Company | >Ingredient | >NDC |
mavacamten drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
mavacamten drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Myokardia Inc | mavacamten | 73625-111 |
| >Company | >Ingredient | >NDC |
mavacamten drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
mavacamten drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Myokardia Inc | mavacamten | 73625-111 |
| >Company | >Ingredient | >NDC |
mavacamten drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: GELATIN
mavacamten drug variants containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| Myokardia Inc | mavacamten | 73625-111 |
| >Company | >Ingredient | >NDC |
mavacamten drug variants not containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
mavacamten drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Myokardia Inc | mavacamten | 73625-111 |
| >Company | >Ingredient | >NDC |
mavacamten drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
mavacamten drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Myokardia Inc | mavacamten | 73625-111 |
| >Company | >Ingredient | >NDC |
mavacamten drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
mavacamten drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| Myokardia Inc | mavacamten | 73625-111 |
| >Company | >Ingredient | >NDC |
mavacamten drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
mavacamten drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Myokardia Inc | mavacamten | 73625-111 |
| >Company | >Ingredient | >NDC |
mavacamten drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
mavacamten drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Myokardia Inc | mavacamten | 73625-111 |
| >Company | >Ingredient | >NDC |
mavacamten drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
